Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

President Calls For Almost $100M More In Funding For FDA Device Activities In 2020

Executive Summary

The current administration would use an additional $98m in congressional budget authority in the 2020 fiscal year for FDA’s medical device efforts to modernize its regulatory approach for technology development, to enable device safety issues to be monitored more closely, and to advance new approaches for regulating digital health technologies and breakthrough devices.

You may also be interested in...



US House Subpanel Would Give FDA Device Center An 8.5% Raise In 2020

A House subpanel overseeing US FDA spending approved an 8.5% boost – $33 million additional – in the agency’s device center funding for 2020, over 2019 levels. 

FDA’s 2020 Device Budget Would Focus On Safety, Cybersecurity, Bringing Medtech 'Home'

US FDA intends to use device-center dollars in its fiscal year 2020 budget on medical product safety, bolstering cybersecurity, device oversight modernization, and an initiative called “Bring Medtech Manufacturing Home,” among other priorities.

Scott Gottlieb Calls It Quits After An Active Tenure At US FDA

The commissioner says he will step down next month, leaving a legacy of active policy development, but also a lot of initiatives and pilot projects that are in the middle of being implemented.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT124772

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel